IXHL
HealthcareIncannex Healthcare Inc.
$0.40
+$0.01 (+1.54%)
Jan 5, 2026
Price History (1Y)
Analysis
Incannex Healthcare Inc. is a company in the healthcare sector, specifically operating within the drug manufacturers - specialty & generic industry. The company's market capitalization stands at $137.14 million, indicating its relatively small scale compared to larger players in the industry. With 12 employees, it is also one of the smaller companies in terms of personnel. From a financial health perspective, Incannex Healthcare has reported significant losses with a net income (TTM) of -$47,872,000 and EBITDA of -$22,850,000. The company's operating margin stands at -191625.0%, and its profit margin is 0.0%. Its returns on equity and assets are also negative, at -114.5% and -30.3%, respectively. However, the company has a relatively low debt to equity ratio of 0.27. The company's valuation metrics are notable, with a forward P/E of -0.20 and an EV/EBITDA of -2.71. The price to book ratio is 1.79, while the price to sales ratio is 11428.33. Despite these numbers, Incannex Healthcare does not pay dividends, as indicated by its payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Incannex Healthcare Inc.
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Visit website →Key Statistics
- Market Cap
- $137.14M
- P/E Ratio
- N/A
- 52-Week High
- $2.25
- 52-Week Low
- $0.08
- Avg Volume
- 21.20M
- Beta
- 2.59
Company Info
- Exchange
- NCM
- Country
- Australia
- Employees
- 12